

Item 3.01.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On July 12, 2018, CEL-SCI received a letter from the NYSE American, its current listing exchange, which advised CEL-SCI that, based upon its March 31, 2018 10-Q report, CEL-SCI was noncompliant with the following continued listing standards of the NYSE American:

Stockholders' equity of \$2.0 million or more if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years (Section 1003(a)(i));

Stockholders' equity of \$4.0 million or more if it has report losses from continuing operations and/or net losses in three of its four most recent fiscal years (Section 1003(a)(ii)); and

Stockholders' equity of \$6.0 million or more if it has report losses from continuing operations and/or net losses in its five most recent fiscal years (Section 1003(a)(iii)).

CEL-SCI can maintain its listing by submitting a plan of compliance by August 13, 2018. This plan must advise of actions CEL-SCI has taken or will take to regain compliance with the continued listing standards by January 14, 2019. CEL-SCI intends to submit such a plan by August 13, 2018. If the plan is not acceptable, or CEL-SCI does not make sufficient progress under the plan to reestablish compliance by January 14, 2019, the staff of the exchange may initiate proceedings to delist CEL-SCI's securities from the NYSE American. CEL-SCI may appeal a delisting determination in accordance with the rules of the exchange.

In addition, the NYSE American will not normally remove the securities of an issuer which is otherwise below the stockholders' equity criteria noted above if the issuer has a market capitalization of at least \$50 million.

The letter from the NYSE American has no current effect on the listing of CEL-SCI's securities on the exchange.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CEL-SCI CORPORATION

Date: July 13, 2018 By: /s/ Geert Kersten
Geert Kersten
Chief Executive Officer